# Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembroluxumab alone.

*biotech · news · 2025-10-20 · The Manila Times*

## Key points

- Cylembio plus pembrolizumab achieved 19.4 months mPFS versus 11.0 months with pembrolizumab alone.
- The trial narrowly missed PFS primary endpoint statistical significance with a p-value of 0.0558.
- Combination therapy improved PFS across PD-L1-negative, BRAFV600-mutated, and elevated LDH subgroups without added systemic toxicity.
- Post-hoc analysis excluding prior anti-PD-1 therapy showed mPFS of 24.8 vs 11.0 months.
- Phase 2 basket trial showed durable responses in NSCLC and SCCHN with no new safety signals.

**Companies:** Merck & Co., Inc., IO Biotech
**Countries:** United States, Denmark, Germany, Turkey, Israel, South Africa, Spain, United Kingdom

[Read the full story on The Manila Times](https://www.manilatimes.net/2025/10/20/tmt-newswire/globenewswire/io-biotech-presents-phase-3-results-for-cylembio-plus-keytruda-pembrolizumab-in-first-line-advanced-melanoma-at-esmo-2025/2203892)

---

Canonical: https://newsio.io/n/433d1cc4-ed9f-4d9a-bc0e-3faacecce680/cylembio-plus-pembrolizumab-achieved-a-clinically-relevant-19-4-months-median-pr
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works